Literature DB >> 393427

m-AMSA and PALA: two new agents in cancer chemotherapy.

M Rozencweig, D D Von Hoff, R L Cysyk, F M Muggia.   

Abstract

4'-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA) and N-(phosphonacetyl)-L-aspartate (PALA) are two new anticancer agents that have been recently introduced into clinical investigation. This review summarizes the preclinical information that has accumulated with these compounds as well as the very preliminary data presently available from early clinical trials. This information indicates the promising potential of m-AMSA and PALA in the treatment of cancer.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 393427     DOI： 10.1007/bf00262414

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  34 in total

1.  Induction of limited DNA damage by the antitumor agent Cain's acridine.

Authors:  N B Furlong; J Sato; T Brown; F Chavez; R B Hurlbert
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

2.  Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.

Authors:  D D Von Hoff; M Rozencweig; W T Soper; L J Helman; J S Penta; H L Davis; F M Muggia
Journal:  Cancer Treat Rep       Date:  1977-08

3.  The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats.

Authors:  R L Cysyk; D Shoemaker; R H Adamson
Journal:  Drug Metab Dispos       Date:  1977 Nov-Dec       Impact factor: 3.922

4.  Anthracycline derivatives in new drug development programs.

Authors:  M Rozencweig; C De Sloover; D D Von Hoff; H J Tagnon; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979-05

5.  An assessment of the immunosuppressive activity of the anti-tumour compound--4'-((9-acridinyl)amino)methanesulphon-m-anisidide (m-AMSA).

Authors:  G C Baguley; E M Falkenhaug; J M Rastrick; J Marbrook
Journal:  Eur J Cancer       Date:  1974-03       Impact factor: 9.162

6.  Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.

Authors:  T Yoshida; G R Stark; J Hoogenraad
Journal:  J Biol Chem       Date:  1974-11-10       Impact factor: 5.157

7.  Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.

Authors:  R K Johnson
Journal:  Biochem Pharmacol       Date:  1977-01-01       Impact factor: 5.858

8.  Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.

Authors:  R K Johnson; E A Swyryd; G R Stark
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

9.  The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.

Authors:  B F Cain; G J Atwell
Journal:  Eur J Cancer       Date:  1974-08       Impact factor: 9.162

10.  Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.

Authors:  D D Von Hoff; K Howser; P Gormley; R A Bender; D Glaubiger; A S Levine; R C Young
Journal:  Cancer Treat Rep       Date:  1978-10
View more
  5 in total

1.  Effectiveness of AMSA alone or in combination with radiation on murine fibrosarcoma pulmonary nodules.

Authors:  D J Grdina; S Jones; N Hunter
Journal:  Clin Exp Metastasis       Date:  1984 Jul-Sep       Impact factor: 5.150

2.  Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.

Authors:  C Greco; G Zupi; G Badaracco
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Enhanced killing of mammalian cells by radiation combined with m-AMSA.

Authors:  P B Roberts; B C Millar
Journal:  Br J Cancer       Date:  1980-11       Impact factor: 7.640

4.  Clonal variation in the sensitivity of B16 melanoma to m-AMSA.

Authors:  T C Stephens; J H Peacock
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

5.  The Open Form Inducer Approach for Structure-Based Drug Design.

Authors:  Daniel Ken Inaoka; Maiko Iida; Toshiyuki Tabuchi; Teruki Honma; Nayoung Lee; Satoshi Hashimoto; Shigeru Matsuoka; Takefumi Kuranaga; Kazuhito Sato; Tomoo Shiba; Kimitoshi Sakamoto; Emmanuel Oluwadare Balogun; Shigeo Suzuki; Takeshi Nara; Josmar Rodrigues da Rocha; Carlos Alberto Montanari; Akiko Tanaka; Masayuki Inoue; Kiyoshi Kita; Shigeharu Harada
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.